Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans.
We report an 81-year-old man with arteriosclerosis obliterans with sharp rest pain of the left lower leg below the knee that was resistant to conventional drug therapy. Gene therapy using hepatocyte growth factor (HGF) was performed, following which the symptoms remarkably improved. Magnetic resonance (MR) angiography did not detect any development of collateral vessels following gene therapy; however, technetium-99m-methoxyisobutylisonitrile (Tc-99m)-MIBI scintigraphy revealed the development of micro-circulation in the lower leg following HGF gene therapy. This is the first report on the usefulness of Tc-99m-MIBI scintigraphy to evaluate the effectiveness of HGF gene therapy for peripheral arteriosclerosis obliterans.
Yamagami
Takuji
T
Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. yamagami@koto.kpu-m.ac.jp
Kanda
Keiichi
K
Okuyama
Chio
C
Nishimura
Tsunehiko
T
D000369:Aged, 80 and over; D050197:Atherosclerosis / Q000000981:diagnostic imaging* / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D017228:Hepatocyte Growth Factor / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D016491:Peripheral Vascular Diseases / Q000000981:diagnostic imaging* / Q000235:genetics / Q000628:therapy*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D017228:Hepatocyte Growth Factor; D017256:Technetium Tc 99m Sestamibi